Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advertisement
Laurence Albiges, MD, PhDLocalized Renal Cell Carcinoma | June 10, 2024
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
View More
Katy MarshallLocalized Renal Cell Carcinoma | May 10, 2024
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Katy MarshallLocalized Renal Cell Carcinoma | May 3, 2024
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Jonathan Afari, MDLocalized Renal Cell Carcinoma | April 24, 2024
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Zachary BessetteLocalized Renal Cell Carcinoma | April 8, 2024
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Emily MenendezLocalized Renal Cell Carcinoma | March 28, 2024
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Emily MenendezLocalized Renal Cell Carcinoma | March 8, 2024
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
Emily MenendezLocalized Renal Cell Carcinoma | February 15, 2024
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Viktor Grünwald, MD, PhDASCO GU Symposium 2024 | January 30, 2024
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
Zachary BessetteASCO GU Symposium 2024 | January 27, 2024
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Katy MarshallASCO GU Symposium 2024 | January 30, 2024
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
Emily MenendezLocalized Renal Cell Carcinoma | March 11, 2024
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Katy MarshallLocalized Renal Cell Carcinoma | December 22, 2023
The retrospective study sought to determine if surgery would benefit patients and identify prognostic factors.
Katy MarshallSUO 2023 | December 18, 2023
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Zachary BessetteSUO 2023 | December 18, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Zachary BessetteSUO 2023 | November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Emily Menendez2023 IKCS: North America | March 11, 2024
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Katy Marshall2023 IKCS: North America | March 11, 2024
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Zachary Bessette2023 IKCS: North America | March 11, 2024
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Advertisement
Advertisement
Advertisement